Latest headlines
AbbVie News
The latest AbbVie (ABBV) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these ABBV headlines next to the live AbbVie Fear and Greed Index.
Latest AbbVie Headlines60
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
prnewswire.com · Jun 26, 2026
Lilly, J&J and AbbVie Hit New Highs
gurufocus.com · Jun 26, 2026
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
prnewswire.com · Jun 26, 2026
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
fool.com · Jun 25, 2026
Is AbbVie a Buy After Its Purchase of Apogee?
fool.com · Jun 25, 2026
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
247wallst.com · Jun 25, 2026
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
247wallst.com · Jun 24, 2026
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
gurufocus.com · Jun 24, 2026
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
businesswire.com · Jun 24, 2026
AbbVie's $11 Billion Immunology Bet
forbes.com · Jun 24, 2026
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
zacks.com · Jun 24, 2026
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
247wallst.com · Jun 24, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
prnewswire.com · Jun 24, 2026
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
247wallst.com · Jun 24, 2026
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
benzinga.com · Jun 23, 2026
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
zacks.com · Jun 23, 2026
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates
proactiveinvestors.com · Jun 23, 2026
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
prnewswire.com · Jun 23, 2026
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
247wallst.com · Jun 23, 2026
G50 Corp strikes high-grade gold at first White Caps core hole in Nevada
proactiveinvestors.com · Jun 23, 2026
3 Monster Stocks to Hold for the Next 10 Years
fool.com · Jun 23, 2026
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
prnewswire.com · Jun 23, 2026
Empire Metals to host investor presentation on Pitfield progress
proactiveinvestors.com · Jun 23, 2026
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
gurufocus.com · Jun 23, 2026
Metals One builds 5.57% stake in newly listed Talon Resources
proactiveinvestors.com · Jun 23, 2026
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
prnewswire.com · Jun 23, 2026
Why AbbVie Stock Jumped Today
fool.com · Jun 22, 2026
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
fool.com · Jun 22, 2026
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
fool.com · Jun 22, 2026
AbbVie Inc (ABBV) Shares Surge 6.2% -- What GF Score of 82 Tells Investors
gurufocus.com · Jun 22, 2026
AbbVie Inc. (ABBV) M&A Call Transcript
seekingalpha.com · Jun 22, 2026
Nasdaq slides but Dow closes higher as investors ditch megacap tech
proactiveinvestors.com · Jun 22, 2026
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline
gurufocus.com · Jun 22, 2026
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
zacks.com · Jun 22, 2026
Dow Jones still in the green but Nasdaq drops as hawkish Fed still looms
proactiveinvestors.com · Jun 22, 2026
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
youtube.com · Jun 22, 2026
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
youtube.com · Jun 22, 2026
AbbVie to acquire Apogee Therapeutics in $10.9B deal
proactiveinvestors.com · Jun 22, 2026
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
benzinga.com · Jun 22, 2026
5 Things to Know Before the Stock Market Opens
investopedia.com · Jun 22, 2026
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
wsj.com · Jun 22, 2026
Breakfast News: AbbVie's $11 Billion Pounce
fool.com · Jun 22, 2026
Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.
barrons.com · Jun 22, 2026
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
reuters.com · Jun 22, 2026
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
prnewswire.com · Jun 22, 2026
Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms
proactiveinvestors.com · Jun 22, 2026
5 Dividend Stocks to Buy and Hold Forever
fool.com · Jun 22, 2026
3 Excellent Dividend Stocks to Buy on the Dip
fool.com · Jun 22, 2026
AbbVie would gain an experimental eczema drug by buying biotech: report
marketwatch.com · Jun 20, 2026
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
reuters.com · Jun 19, 2026
AbbVie: Immunology Cash Flow Funds Oncology Expansion
seekingalpha.com · Jun 19, 2026
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
zacks.com · Jun 18, 2026
AbbVie Declares Quarterly Dividend
prnewswire.com · Jun 18, 2026
3 Dividend Stocks That Pay You More Every Single Year
247wallst.com · Jun 17, 2026
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Jun 17, 2026
AbbVie: Maintaining My Strong Buy Rating After Label Expansion
seekingalpha.com · Jun 16, 2026
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
247wallst.com · Jun 16, 2026
AbbVie Stock Will Hit $300 on This Date
247wallst.com · Jun 16, 2026
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
zacks.com · Jun 16, 2026
Health Care ETFs: XLV Delivers Low Fees and Solid Returns
fool.com · Jun 16, 2026
Why Is AbbVie Up or Down Today?
When AbbVie (ABBV) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a ABBV move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why AbbVie is up or down today.
How AbbVie News Affects the Price
News does not move the AbbVie (ABBV) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the AbbVie Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in AbbVie trading volume. That is the chain to watch: headline, sentiment, volume, then the ABBV price.
Trade the AbbVie News With Sentiment
Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch AbbVie trading volume spike on a big story, check the AbbVie price history for context, follow the live ABBV price, see the AbbVie price prediction, and read the AbbVie Fear and Greed Index for mood.
How do you feel about AbbVie?
1DFrequently asked questions
Why is AbbVie up or down today?
What is the latest AbbVie news?
Where does AbbVie news come from?
How often is AbbVie news updated?
How does AbbVie news relate to its Fear and Greed Index?
Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.
About CFGI
The per-asset sentiment record.
CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and more than 100 individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.
Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.